Ajanta Pharma Declares ₹28 Interim Dividend as Q2 Profit Rises 11%, Shares Climb to ₹2,932

Ajanta Pharma Ltd’s shares experienced a modest increase of 0.37%, reaching ₹2,932.00 on the BSE today. On October 28, the company announced its first interim dividend of ₹28 per share, amounting to ₹350 crore. The record date for this dividend has been set for November 6, with payments expected to occur after November 15, 2024.

Financial Performance (Q2 FY25):

• Net Profit: Ajanta Pharma reported an 11% year-over-year increase in net profit, rising to ₹216 crore from ₹195 crore in the same quarter of the previous year.
• Revenue from Operations: Revenue grew by 15% year-over-year, totaling ₹1,187 crore, compared to ₹1,028 crore in Q2 FY24.
• EBITDA: The company’s EBITDA climbed to ₹311 crore, up from ₹291 crore in the same period last year.
• Cash Flow from Operations: Cash flow from operations stood at ₹776 crore at the end of the quarter.

Share Performance:

• 52-Week High: ₹3,485.75 (recorded on September 12, 2024).
• 52-Week Low: ₹1,730.20 (recorded on October 30, 2023).
• Market Capitalization: Approximately ₹36,531.17 crore.
• Recent Trends: The stock has slipped 12.60% in the last month, but it has gained 35% year-to-date. Over the past two years, the stock has surged 122%, and it has increased by 326% over the last five years.

Dividend Details:

• Dividend Yield: At the current share price of ₹2,932.00, Ajanta Pharma offers a dividend yield of 0.89%.
• Dividend History: The company has recommended 24 dividends since September 5, 2001. In the past year, it declared an equity dividend of ₹26.00 per share.

Analyst Recommendations:

According to A. R. Ramachandran, an independent SEBI research analyst, Ajanta Pharma is currently bearish on daily charts, facing strong resistance at ₹3,010. A close above this resistance level could set a target of ₹3,233 in the near term, with strong support identified at ₹2,910.

Disclaimer: This information is for educational and informational purposes only and should not be considered financial advice. Please consult with a financial advisor before making any investment decisions.